Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RxNews Recap for Friday 01-08-10

Below is a list of the healthcare sector companies that made news in the healthcare sector on Friday, January 08, 2010. This list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases.

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has been invited to present at the Sidoti Microcap 2010 Investor Conference on Monday, January 11, 2010 at 11:50 PM EST.

athenahealth, Inc. (NASDAQ: ATHN), a leading provider of internet-based business services to physician practices, today announced that according to a new KLAS Report Ambulatory EMR: On Track for Meaningful Use?, athenaClinicalsSM, the Company’s web-based electronic health record (EHR) service offering, achieved 100% client confidence in its ability to enable them to meet 2011 Meaningful Use standards under the HITECH Act.

Advanced Cell Technology, Inc. (OTCBB:ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (NYSE:IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the First Quarter of Fiscal Year 2010 on Tuesday, January 26, 2010 prior to the opening of trading on the New York Stock Exchange.

CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today confirmed that Arcadia Capital Advisors, LLC and its principal Richard Rofé, who hold approximately 12% of outstanding shares, have filed with the Securities and Exchange Commission (SEC) notice of intention of Mr. Rofé to make an unsolicited contingent offer to purchase the remaining shares of common stock of CPEX for $14.00 per share.

Genzyme Corporation (NASDAQ: GENZ) announced today that Ron Branning, a 30-plus year bio/pharmaceutical veteran specializing in the development of world-class drug and device quality monitoring systems and regulatory compliance management practices, has joined the company as Senior Vice President of Global Product Quality.

GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has converted the convertible preferred stock it previously purchased in November 2009 under the terms described in the financing agreements approved by GTC shareholders in July 2009 into a total of 5.3 million shares of common stock.

Obagi Medical Products, Inc. (NASDAQ:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that it was served January 7, 2010 with a complaint from ZO Skin Health, Inc., a company affiliated with Dr. Zein Obagi, OMP’s original founder.

Mannatech, Incorporated (NASDAQ: MTEX), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of a randomized, double-blind, placebo-controlled study that shows healthy middle-aged adults who took one teaspoon of Ambrotose® complex1 twice daily performed significantly better on memory tasks and were overall more positive in their mood.

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) announced today the appointment of Drayton Virkler as senior director of the Talecris Investor Relations department.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.

Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lawrence D. Stern, Chairman and Chief Executive Officer of Talecris, will present at the 28th Annual J.P. Morgan Healthcare Conference at 8:30 a.m., Wednesday, Jan. 13 at the Westin St. Francis Hotel in San Francisco.

Walgreens (NYSE: WAG)(NASDAQ: WAG), the nation’s largest drugstore chain with more than 70,000 health service providers, is now offering free review sessions to Medicare Part D beneficiaries at all of its more than 7,100 pharmacies throughout the country.

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 28th Annual J.P. Morgan Healthcare Conference.


Disclosure: no positions